How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis

    Closed for comments This consultation ended on at   Request commenting lead permission

    Validity and generalisability of the studies

    • Studies were conducted in China (n=2), Canada (n=1), Germany (n=1), Russian (n=1) and Spain (n=1). UK data came from the NJR, even though the data were for patients who had primary THAs with various approaches for various indications.

    • Patients were followed up no longer than 16 months (6 months in 1 study; 8 months in 2 studies; 1 year in 2 studies; 16 months in 1 study), and long-term data were reported in the NJR implant summary reports (maximum implantation time, 16.5 years).

    • There was variation in patient selection (inclusion criteria). The mean age ranged from 56 to 69 years and mean BMI ranged from 23 to 30 kg/m2.

    • Not all the studies identified the implants used and comparative studies used different implants as well as surgical approaches.

    • Of the 3 randomised controlled trials:

      • Patients were blinded in one trial (Meng 2021) but not blinded in the other 2 trials (Korytkin 2021; Xie 2017).

      • A power analysis was done in the research planning phase in 1 trial (Korytkin 2021).

      • Intention-to-treat analysis was used in 2 trials (Meng 2021; Xie 2017) but not in the other trial (Korytkin 2021).

    • Postoperative rehabilitation plays an important role in muscle strengthening and mobility. Of the 6 included studies, 2 studies provided some information relating to postoperative rehabilitation (Korytkin 2021; Meng 2021).

    • Length of hospital stay varied widely across the studies and social issues might play a role.